The effect of oral acyclovir (approximately 40 mg/kg daily in four divided doses) against primary and secondary viraemia of varicella zoster virus (VZV) was examined in 27 children susceptible to VZV who were exposed to the virus in their families and their clinical features were compared with those of 19 nontreated subjects. The infection was confirmed by a fluorescent antibody to membrane antigen assay in 11 (85%) of 13 children who received acyclovir for the first seven days after exposure to VZV and in 11 (79%) of 14 who received acyclovir for the next seven days. The geometric mean antibody titre of the former group was significantly higher than that of the latter group. Varicella developed in 10 (91%) and was subclinical in one (90/%) in the former group, whereas a very mild disease occurred in three (27%) and was subclinical in eight (73%/o) in the latter group. The severity of varicella was significantly greater in the former group than that in the latter group. On the other hand, all of the control group developed typical varicella and their clinical features were more severe than those of the acyclovir administered group. These data indicate that oral acyclovir more effectively inhibits replication of VZV in secondary viraemia than that of the primary viraemia.
Varicella is a common contagious disease of childhood that is caused by primary infection with varicella zoster virus (VZV). It is usually a benign and self limited disease in normal children, but the disease is generally severe in susceptible newborn infants, immunocompromised children, and adults.1 It is also well known that secondary cases in households are more severe than primary cases.2 Although the pathogenesis ofvaricella is not well understood because of the lack of susceptible experimental animals3 and the fastidious nature of VZV in the laboratory,4 the disease is believed to follow dual VZV viraemia. 5 Secondary viraemia has been demonstrated between five days before and one day after clinical onset of disease,68 however, the presence of primary viraemia is still speculative. Balfour et al and Dunkle et al have reported that acyclovir is a safe treatment which reduces the duration and severity of varicella in normal children when it is initiated during the first 24 hours of the rash. 9 10 Recently, we found that varicella can be prevented or modified by administration of oral acyclovir late in the incubation period of the disease. 11 In the present study, we compared the effect of oral acyclovir against primary and secondary viraemia during the incubation period of varicella.
Patients and Methods

STUDY POPULATION
Between March and June 1992, 27 children who had no history of varicella and had been exposed to a sibling with varicella were enrolled in this study. The subjects were separated in two groups (first and second groups) and received acyclovir (30-80 mg/kg daily in four divided doses) orally for seven days during the incubation period of varicella. The first day of exposure to a sibling with varicella was assigned as day 0. The first group consisted of 13 children (seven boys and six girls) with a mean age of 2-1 years (range from 06 months-5 years), who received acyclovir (mean 44 mg/kg, range from 35-80 mg/kg) starting between day 0 and day 3 (mean day 1.4) . The second group consisted of 14 children (nine boys and five girls) with a mean age of 2-9 years (range from 0 5-9 years), who received acyclovir (mean 49 mg/lkg, range from 30-80 mg/kg) starting between day 6 and day 10 (mean day . Their clinical features were compared with those of 19 age matched subjects (seven boys and 12 girls) with a mean age of 2-9 years (range from 0-3-8 years), who were exposed to the virus in their families but did not receive acyclovir. A complete medical history and physical examination was obtained by authors. Informed consent was obtained from parents of the subjects enrolled in this study after the project was thoroughly explained. Children with a history of immune deficiency, those taking cytotoxic or immunosuppressive drugs, those who had received immunoglobulin within the past four weeks, and those who had been vaccinated against VZV were excluded from participation.
EVALUATION OF SEVERITY OF VARICELLA
The presumed day of varicella onset was assigned as 14 days after exposure to a sibling with varicella. Clinical evaluations were performed on approximately day 14 (acute phase) and on day 28 to day 42 (convalescent phase), respectively. If varicella exanthem appeared, the number of lesions was counted tThe first and second groups had significantly lower incidence of fever than the control group (p<0 01).
The question remains as to whether a higher dose of acyclovir more effectively prevents or modifies the clinical course of the disease in the first group than that observed in the present study.
Commentary
Varicella is common, with a 1992 general practitioner consultation rate >600 per 100 000 population. Almost all infected children suffer at least a moderate constitutional illness, but the otherwise normal child will usually have no new lesions after four days and complications are rare. We must ask whether we want to interfere with varicella, an essentially benign illness in normal children. There is a growing pressure to intervene by administration of acyclovir within the first 24 Information so far from children receiving acyclovir for varicella shows an adequate humoral and cellular response. However, the immune response to primary herpes simplex infection may be decreased after treatment with acyclovir, and some may suffer a more intense first herpetic recurrence. Might acyclovir given in the incubation period for varicella increase the problems of zoster? Suga et al seem to suggest in their discussion that we should find a higher dose to prevent more effectively clinical illness. Perhaps we should rather try to realise a dose that would allow mild clinical illness (we would know that the child had had varicella), and produce an effective and lasting antibody response, or simply treat the secondary family 
